ClosedPublished 16 Oct 2024

Celularity Inc. /
Sequence LifeScience, Inc.

Celularity adds Rebound product through Sequence asset purchase

Buy side: Celularity Inc.
Buy sideCelularity Inc.
Target: Sequence LifeScience, Inc.
TargetSequence LifeScience, Inc.
Source · 16 Oct 2024Source-verified
Buy side: Celularity Inc.
Buy sideCelularity Inc.
Target: Sequence LifeScience, Inc.
TargetSequence LifeScience, Inc.
01 / BuyerCelularity Inc.
02 / TargetSequence LifeScience, Inc.
Source-verified
01

What happened

Celularity Inc. acquired certain assets from Sequence LifeScience, Inc., including Rebound, a full thickness placental-derived allograft matrix product. The transaction closed on Oct. 9, 2024.

The aggregate consideration was $5,500,000, including an upfront cash payment, monthly milestone payments, and a credit for a previous payment.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

Celularity adds Rebound product through Sequence asset purchase

This document is the source for the companies, stage and people on this page.

Source-verified
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Closed

    The source this page is built from.

    Source-verified
  2. Published by the source

    The source this page is built from.

    Source-verified

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request an inviteAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.